CHMP issues positive opinion on Richterʼs Esmya® 5 mg


The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the company’s application to extend the indication of Esmya® 5 mg tablets (ulipristal acetate) to long term repeated intermittent treatment of moderate to severe symptoms of uterine fibroids, Gedeon Richter Plc. said today in a press release.

The CHMP positive opinion will be forwarded to the European Commission, which is expected to amend the EU marketing authorization for Esmya® 5 mg applicable to all countries of European Union, within two months from the opinion.

Uterine fibroids are the most common benign, solid tumours of the female genital tract, affecting between 20 and 25 percent of women of reproductive age. The condition is characterized by excessive uterine bleeding, anaemia, pain, frequent urination or incontinence, and infertility.

Esmya® 5 mg containing ulipristal acetate, a new chemical entity, is a first-in-class, orally active, selective progesterone receptor modulator which reversibly blocks the progesterone receptors in target tissues, Richter said in the press release. The repeated intermittent 3-month treatment courses of once-a-day oral therapy is effective to stop uterine bleeding, correct anaemia, shrink fibroid volume and improve quality of life, the press release added. Esmya® has been developed by PregLem, the wholly owned subsidiary of Richter.

Richterʼs consolidated sales were approximately €1.1 bln ($ 1.5 bln), while its market capitalization amounted to €2.1 bln ($ 2.5 bln) in 2014. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas.


Croatia Paying MOL USD 235 mln Award Energy Trade

Croatia Paying MOL USD 235 mln Award

Gov't Guarantees on Liabilities Climb Over 9% of GDP in 2021 Government

Gov't Guarantees on Liabilities Climb Over 9% of GDP in 2021

OXO Technologies Looks for New HQ Elsewhere in EU Innovation

OXO Technologies Looks for New HQ Elsewhere in EU

Hungary Adopting Performance-based Financing for Arts Art

Hungary Adopting Performance-based Financing for Arts


Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.